This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Discovery Labs Presents New SURFAXIN® And AFECTAIR® Data At 2012 Hot Topics In Neonatology Annual Meeting

WARRINGTON, Pa., Nov. 28, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced it will present both SURFAXIN ® and AFECTAIR ® data at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C.  Hot Topics in Neonatology is an internationally recognized medical meeting dedicated to advancing the practice of neonatology.

Earlier this year, SURFAXIN became the first Food and Drug Administration (FDA)-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk of developing RDS.  Also, in February 2012, the company's AFECTAIR device was registered with the FDA and cleared for marketing in the United States.  AFECTAIR is a proprietary disposable airway connector that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support from either intermittent mechanical ventilation or continuous positive airway pressure.

Discovery Labs presentations at Hot Topics in Neonatology include:
  • Pharmacoeconomic Impact of Bronchopulmonary Dysplasia in Reintubated Infants – Simmons PD and Clayton RG
  • In Vitro Comparison of Albuterol Delivery Using a Novel Neonatal Ventilator Circuit Connector with Three Different Neonatal Ventilators  – Gregory TJ, Henderson C, Mazela J, Boppana V, and Clayton RG

Additionally, a late-breaker platform presentation entitled New insights into effective aerosol therapy in premature infants - Are we ready to inhale surfactants? will provide a comprehensive review of aerosolized treatment options for RDS today and into the future.  This topic, which is relevant to Discovery Labs' aerosolized KL 4 surfactant development candidate, AEROSURF ®, will be presented at 11:45am on December 4 th.

For over 30 years, Hot Topics has been the premier neonatal conference, with more than 1,000 neonatologists and perinatologists attending each year.  For more information about Discovery Labs and its products, attendees can visit Discovery Labs in the Hot Topics in Neonatology Internet Café or visit  

IMPORTANT SAFETY INFORMATIONSURFAXIN (lucinactant) Intratracheal Suspension is intended for intratracheal use only.  The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance.  SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly-supervised clinical setting.  Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.  SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs